<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049165</url>
  </required_header>
  <id_info>
    <org_study_id>CV202-001</org_study_id>
    <nct_id>NCT01049165</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose (BMS-813160) Study</brief_title>
  <official_title>Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-813160 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety and tolerability of single oral
      doses of BMS-813160 in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety will be assessed by clinical laboratory results, ECGs, vital signs, and reported adverse events</measure>
    <time_frame>Dosing through Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-813160</measure>
    <time_frame>9 times after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (Plasma MCP-1)</measure>
    <time_frame>9 times post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (Circulating monocytes)</measure>
    <time_frame>5 times post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (CCR5 phosphorylation and internalization in whole blood)</measure>
    <time_frame>5 times post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Accelerated Intimal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Arm 1 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7 [14C] BMS-813160</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-813160</intervention_name>
    <description>Oral Solution, Oral, 5 mg, Single dose, 1 day</description>
    <arm_group_label>Arm 1 (BMS-813160 or placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-813160</intervention_name>
    <description>Oral Solution, Oral, 20 mg, Single dose, 1 day</description>
    <arm_group_label>Arm 2 (BMS-813160 or placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-813160</intervention_name>
    <description>Oral Solution, Oral, 60 mg, Single dose, 1 day</description>
    <arm_group_label>Arm 3 (BMS-813160 or placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-813160</intervention_name>
    <description>Oral Solution, Oral, 150 mg, Single dose, 1 day</description>
    <arm_group_label>Arm 4 (BMS-813160 or placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-813160</intervention_name>
    <description>Oral Solution, Oral, 300 mg, Single dose, 1 day</description>
    <arm_group_label>Arm 5 (BMS-813160 or placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-813160</intervention_name>
    <description>Oral Solution, Oral, 600 mg, Single Dose, 1 day</description>
    <arm_group_label>Arm 6 (BMS-813160 or placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] BMS-813160</intervention_name>
    <description>Oral Solution, Oral, 150 mg, Single Dose, 1 day</description>
    <arm_group_label>Arm 7 [14C] BMS-813160</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Solution, Oral, 0 mg, Single Dose, 1 day</description>
    <arm_group_label>Arm 1 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_label>Arm 2 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_label>Arm 3 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_label>Arm 4 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_label>Arm 5 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_label>Arm 6 (BMS-813160 or placebo)</arm_group_label>
    <arm_group_label>Arm 8 (BMS-813160 or placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-813160</intervention_name>
    <description>Oral Solution, Oral, 1200 mg, Single dose, 1 day</description>
    <arm_group_label>Arm 8 (BMS-813160 or placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-813160</intervention_name>
    <description>Oral Solution, Oral, 2000 mg, Single Dose, 1 day</description>
    <arm_group_label>Arm 9 (BMS-813160 or placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women (not of child bearing potential) ages 18 to 45

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs, and clinical laboratory determinations

        Exclusion Criteria:

          -  Women of Child Bearing Potential

          -  Organ dysfunction or any clinically significant deviation from normal in medical
             history, physical examination, ECGs, and clinical laboratory determinations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>February 10, 2011</last_update_submitted>
  <last_update_submitted_qc>February 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

